The Ultimate Peptide Tier List

FDA-approved GLP-1 agonist (Ozempic/Wegovy) with the deepest human trial file of any peptide here — 13 evidence-tagged benefits including clinical-level weight-loss data.

FDA-approved dual GIP/GLP-1 agonist (Mounjaro/Zepbound) with superior weight-loss results vs GLP-1 monotherapy in head-to-head RCTs.

Triple-agonist (GLP-1/GIP/glucagon) in Phase 3 trials; one of the strongest emerging metabolic profiles with 15 catalogued benefits.

Bremelanotide is FDA-approved (Vyleesi) for hypoactive sexual desire — one of the few melanocortin peptides with regulatory approval and clinical evidence.

FDA-approved GHRH analog (Egrifta) for HIV-associated lipodystrophy; strong clinical evidence for visceral fat reduction.

FDA-approved GHRH analog used in growth hormone deficiency; clinically studied GH stimulation with a solid safety record.

FDA-approved GLP-1 agonist (Victoza/Saxenda) with proven weight loss, glycemic control, and cardiovascular benefits across multiple RCTs.

The most-studied healing peptide — 15 benefits spanning tendon, ligament, and tissue repair with clinical and anecdotal evidence across 50 citations.

Thymosin Beta-4 fragment with strong preclinical and clinical evidence for systemic tissue repair, angiogenesis, and wound healing.

Copper tripeptide with clinical + preclinical evidence for collagen synthesis, skin rejuvenation, and anti-inflammatory effects across 19 benefits.

Long-acting GHRH analog with clinical evidence for GH/IGF-1 elevation; a cornerstone of GH-stack research.

Selective ghrelin-receptor agonist with 18 evidence-tagged benefits and a reputation for clean GH release with minimal side effects.

Anxiolytic peptide approved in Russia; 26 catalogued benefits spanning anxiety relief, mood, and cognition with clinical + preclinical evidence.

Nootropic peptide approved in Russia; 24 evidence-tagged benefits for memory, neuroprotection, and cognition with a long research history.

Immune-modulating peptide used clinically in hepatitis B and immune support; 51 citations and 12 benefits including infection resistance.

Mitochondrial-derived peptide with clinical evidence for metabolic regulation, insulin sensitivity, and exercise performance.

Telomerase-activating tetrapeptide with 25+ years of research, clinical + preclinical evidence across 16 benefits for aging pathways.

EPO-derived peptide (Cibinetide) evaluated in clinical trials for neuropathic pain and tissue protection; 46 citations.

Delta sleep-inducing peptide with clinical + preclinical evidence for sleep architecture and recovery; 20 benefits but mixed replication.

Alpha-MSH fragment with 20 catalogued benefits spanning anti-inflammatory and wound-healing research; mostly preclinical.

Cognitive enhancer with clinical-stage studies for memory and neurogenesis; promising but early.

Human antimicrobial peptide with clinical evidence for wound healing and infection defense; 53 citations.

Oral GH secretagogue (Ibutamoren) with clinical evidence for GH elevation, muscle, and sleep; strong research base but chronic-use questions remain.

Potent GH-releasing hexapeptide with clinical + preclinical evidence; strong GH response, cardiac-research interest.

GH-releasing peptide with clinical evidence and 51 citations; appetite and cortisol considerations at higher doses.

GH secretagogue with clinical evidence; known for strong appetite stimulation, which may help or hinder depending on goals.

Cellular cofactor with extensive longevity and metabolic research (47 citations); safe but effects are modest and mostly preclinical for aging claims.

Master antioxidant with clinical evidence for liver detox and oxidative stress; safe, well-studied, but benefit ceiling is low for most users.

Thymic peptide with clinical studies showing immune balance and mortality-reduction associations in aging populations.

Prescription nootropic in many countries with clinical evidence for stroke recovery and neuroplasticity; 21 citations.

GLP-1/glucagon dual agonist in Phase 3 trials; promising metabolic profile but not yet approved.

GLP-1/glucagon dual agonist in Phase 2 trials with early weight-loss data; promising but investigational.

HGH fragment studied for fat loss — mostly preclinical + anecdotal (19 benefits but thin human data); effects on body composition remain unproven.

Mitochondrial peptide with centenarian-association data; promising longevity signals but mostly early-stage research.

Senolytic peptide studied for eliminating senescent cells; fascinating mechanism, preclinical-stage evidence.

Reproductive-hormone modulator with clinical interest in fertility; niche applications and modest evidence base.

Long-acting IGF-1 analog used in bodybuilding research; anecdotally popular with limited safety data and WADA prohibition.

Short-acting IGF-1 variant for localized anabolic effects; minimal human data, research-grade only.

IGF-1 splice variant studied for satellite-cell activation; strong mechanistic interest, thin human evidence.

Pegylated MGF with extended half-life; same evidence limitations as MGF with even less research.

Myostatin inhibitor with dramatic muscle-growth potential in animal models; human data are extremely limited.

Vasoactive intestinal peptide with clinical interest in autoimmune and neuroprotective applications; administration challenges limit use.

Bioregulator peptide researched for cognition; mostly Russian literature, small studies.

Brain peptide with clinical use in Russia for stroke and cognition; evidence largely from non-Western literature.

Full-length healing peptide with 53 citations and strong preclinical data; overlaps heavily with TB-500 research.

Neurogenic compound studied for depression and hippocampal growth; early clinical data, mixed results.

CREB-modulating peptide for memory and cognition; preclinical-stage research with limited human evidence.

TREK-1 channel inhibitor studied as an antidepressant; very early-stage evidence.

Melanocortin agonist with clinical evidence for tanning and sexual function; safety concerns (moles, nausea) temper its appeal.

Copper tripeptide for hair and skin; popular in cosmetic research but mostly anecdotal evidence.

PPAR-delta agonist (GW501516) — clinical development was halted over tumor findings in animal studies; potent endurance claims with serious safety baggage.

Rev-ErbA agonist (Stenabolic) with anecdotal endurance claims; extremely poor oral bioavailability and largely unstudied human safety.

Selective androgen receptor modulator; anabolic claims rest on anecdotes, with real concerns about hormonal suppression and liver stress.

Myostatin inhibitor whose clinical trial was terminated; only 1 benefit catalogued and the lean-mass gain was not sustained.

Exercise-mimetic with fascinating metabolic research but only 9 citations and no meaningful human data.

AMPK activator studied for endurance; largely preclinical, WADA-prohibited, and associated with tumor-promotion questions in animal models.